result.Of those patients with normal DMSA, VCUG and UIS, none developed a second febrile UTI.Of those patients with an abnormal DMSA, normal VCUG and UlS, only one developed a second febrile UTI.In children less than two years old, with normal studies (VCUG and U/S), it appears DMSA has little predictive value in the occurrence of a second febrile UTI.

10.1016/s0022-5347(03)80037-x

Cite

Citations (1)

Remembering Hank.

PubMed (2014)

Robert Bahnson

Source

Cite

Citations (0)

Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction

Therapeutic Advances in Urology (2009)

Gregory Lowe Robert Bahnson

Phosphodiesterase type 5 inhibitors (PDE5-i) have become first line therapy for the treatment of erectile dysfunction. Most initial prescriptions for PDE5-i are by primary care practitioners. Urologists must now routinely manage the patient who has failed initial therapy with PDE5-i. Lifestyle modifications can be of benefit to patients. Patient education and optimization of the PDE5-i can result in a successful response. Interestingly, there are reports of up to 60% salvage after changing the PDE5-i utilized. Daily PDE5-i have shown benefit, and treatment of hypogonadism can enhance response to PDE5-i. We review the management of PDE5-i failures with emphasis on noninvasive approaches to gaining improved erectile response to these medications. An algorithm based on the reviewed strategies is proposed to guide clinicians in the treatment of erectile dysfunction.

10.1177/1756287210362069

Cite

Citations (12)

Issue Information - Ed Board

Journal of Surgical Oncology (2016)

Stephen Sener David J. Bentrem Walley Temple Gerald Murphy Erica Byrd

Editorial board

10.1002/jso.24459

Cite

Citations (1)

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

Urologic Oncology Seminars and Original Investigations (1995)

Jennifer L. Osborn Gary G. Schwartz David C. Smith Robert Bahnson Roger Day

Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D(3) in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)(2)D(3)) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)(2)D(3) was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)(2)D(3) given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)(2)D(3) is limited by hypercalcemia.

Refractory (planetary science)

10.1016/1078-1439(95)00061-5

Cite

Citations (172)